Cross-Match as an Immuno-Oncological Risk Factor for Hepatocellular Carcinoma Recurrence and Inferior Survival After Living Donor Liver Transplantation: A Call for Further Investigation.

Cheng-Maw Ho, Rey-Heng Hu, Yao-Ming Wu, Ming-Chih Ho, Po-Huang Lee

Abstract read

In one paragraph

Article in Clinical Medicine Insights. Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Editorial: Transplant Oncology of Liver Malignancies.Frontiers in surgery · 2021
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Cheng-Maw HoDepartment of Surgery, National Taiwan University Hospital and College of Medicine, Taipei.ORCID https://orcid.org/0000-0003-1874-7615

Rey-Heng HuDepartment of Surgery, National Taiwan University Hospital and College of Medicine, Taipei.

Yao-Ming WuDepartment of Surgery, National Taiwan University Hospital and College of Medicine, Taipei.ORCID https://orcid.org/0000-0002-1720-7863

Ming-Chih HoDepartment of Surgery, National Taiwan University Hospital and College of Medicine, Taipei.

Po-Huang LeeDepartment of Surgery, National Taiwan University Hospital and College of Medicine, Taipei.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe success of immunotherapy for patients with hepatocellular carcinoma (HCC) suggests that immune dysregulation occurs in HCC patients. This warrants an immuno-oncological risk assessment in the platform of liver transplantation.

methodsThis retrospective single-center study analyzed risk factors for-particularly cross-matching performed through conventional complement-dependent cytotoxicity cross-match tests-and the outcomes of HCC recurrence following living donor liver transplant.

resultsA total of 71 patients were included. The median follow-up period was 29.1 months; 17 (23.9%) patients had posttransplant HCC recurrence, and their 1-, 3-, and 5-year-survival rates were 70.6%, 25.7%, and 17.1%, respectively, which were inferior to those of patients without HCC recurrence (87.0%, 80.7%, and 77.2%, respectively;

conclusionsAdditional large-scale studies are required to validate positive cross-match as an immuno-oncological factor associated with HCC recurrence and inferior patient survival.

Indexed as

cross-matchHepatocellular carcinomaimmuno-oncologyliver transplantationrecurrencerisk factor

Identifiers

PMID33343205

DOI10.1177/1179554920968774

PMCPMC7731698

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.